Lin Shi

Dr. Lin Shi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
TLTingting Li
Tingting Li
RLRuifeng Li
Ruifeng Li
XDXuan DONG
Xuan DONG
LSLin Shi
Lin Shi
MLMiao Lin
Miao Lin
CLCheng Li
Cheng Li
Genomic studies of cancer cell alterations, such as mutations, copy number variations (CNVs), and translocations, greatly promote our understanding of the genesis and development of cancers. However, the 3D genome architecture of cancers remains less studied due to the complexity of cancer genomes and technical difficulties. To explore the 3D genome structure in clinical lung cancer, we performed Hi-C experiments using paired normal and tumor cells harvested from patients with lung cancer, combining with RNA sequenceing analysis. We demonstrated the feasibility of studying 3D genome of clinical lung cancer samples with a small number of cells (1 × 104), compared the genome architecture between clinical samples and cell lines of lung cancer, and identified conserved and changed spatial chromatin structures between normal and cancer samples. We also showed that Hi-C data can be used to infer CNVs and point mutations in cancer. By integrating those different types of cancer alterations, we showed significant associations between CNVs, 3D genome, and gene expression. We propose that 3D genome mediates the effects of cancer genomic alterations on gene expression through altering regulatory chromatin structures. Our study highlights the importance of analyzing 3D genomes of clinical cancer samples in addition to cancer cell lines and provides an integrative genomic analysis pipeline for future larger-scale studies in lung cancer and other cancers.

7 September 2017 in Molecular and Cellular Therapies
Verified
Journal Article
Open access
LWLingyan Wang
Lingyan Wang
JHJiayun Hou
Jiayun Hou
MZMinghuan Zheng
Minghuan Zheng
LSLin Shi
Lin Shi
Actinidia Chinensis Planch roots (acRoots) are used to treat many cancers, although the anti-tumor mechanism by which acRoots inhibit cancer cell growth remains unclear. The present study aims at investigating inhibitory effects of acRoots on human lung cancer cells and potential mechanisms. Our data demonstrate that the inhibitory effects of acRoots on lung cancer cells depend on genetic backgrounds and phenotypes of cells. We furthermore found the expression of metabolism-associated gene profiles varied between acRoots-hypersensitive (H460) or hyposensitive lung cancer cells (H1299) after screening lung cancer cells with different genetic backgrounds. We selected retinoic acid receptor beta (RARB) as the core target within metabolism-associated core gene networks and evaluated RARB changes and roles in cells treated with acRoots at different concentrations and timeframes. Hypersensitive cancer cells with the deletion of RARB expression did not response to the treatment with acRoots, while RARB deletion did not change effects of acRoots on hyposensitive cells. Thus, it seems that RARB as the core target within metabolism-associated networks plays important roles in the regulation of lung cancer cell sensitivity to acRoots.

3 June 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
YXYiding Xu
Yiding Xu
LCLei Chen
Lei Chen
JLJie Liu
Jie Liu
QWQin Wang
Qin Wang
XZXiaodan Zhu
Xiaodan Zhu
HJHongni Jiang
Hongni Jiang
Fluconazole is key for pulmonary cryptococcosis (PC), but its hepatotoxicity (HT) risk is unclear. This study characterized fluconazole-induced liver injury in HIV-negative PC patients and explored its mechanism. We integrated clinical cohort analysis ( n = 123), network toxicology, molecular docking, and transcriptomics. HT incidence was 23.6%, predominantly cholestatic (55.2%). Immunocompromised status independently increased HT risk (aRR = 2.67, P = 0.004). Baseline ALT >16.5 U/L was the best predictor (AUC = 0.69) among liver enzymes, which showed modest discriminatory value. A model combining liver enzymes, immune status, and comedications achieved superior prediction (AUC = 0.76). Mechanistically, AKT1, ERBB2, and KDR were identified as potential core targets. Transcriptomics confirmed their significant downregulation in general cholestasis models, and molecular docking demonstrated favorable affinity binding with fluconazole (strongest for KDR: −6.5 kcal/mol). In conclusion, baseline liver enzymes and immune status are critical risk factors for fluconazole-induced HT, and fluconazole-induced cholestatic injury may involve the dysregulation of signaling pathways centered on AKT1, ERBB2, and KDR, suggesting potential targets for monitoring.

26 August 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YXYiding Xu
Yiding Xu
RLRongkui Luo
Rongkui Luo
HJHongni Jiang
Hongni Jiang
LSLin Shi
Lin Shi
Background Multiple primary cancers (MPC) involving both thyroid and lung are diagnostically challenging. The co-expression of TTF-1 and p40 in non-small cell lung cancer (NSCLC) defines a rare, aggressive subtype. Distinguishing between metastatic thyroid cancer and a second primary lung cancer, especially with overlapping features, is crucial for appropriate management. Case presentation We report a 70-year-old female with a history of papillary thyroid carcinoma (PTC) who developed multiple lung nodules. Initial biopsies confirmed a primary TTF-1/p40 co-expressing NSCLC, initially staged as metastatic lung cancer. Serial TGAb > 4000 IU/mL persisting despite I-131, with discordant radiologic response between unilateral right lower lobe lesion and bilateral nodules, served as the clinical clue prompting re-classification. Subsequent multidisciplinary review led to the revised diagnosis of MPC: metastatic PTC alongside a synchronous TTF-1/p40 co-expressing NSCLC. Following several lines of treatment, the patient received anlotinib combined with a PD-L1 inhibitor (sintilimab), which was associated with tumor regression enabling subsequent surgical resection of the lung cancer. Post-operatively, she continued this regimen with sustained disease control. Conclusion This case underscores the diagnostic pitfalls in differentiating MPC from solitary metastatic disease. It highlights the critical role of integrated clinicopathological correlation, serial biomarker assessment, and multidisciplinary discussion in achieving an accurate diagnosis, which is the cornerstone for personalized treatment strategies in complex oncological cases. The experience suggests that combined anti-angiogenic and immunotherapy may have a role in rendering selected complex cases resectable, although this requires further investigation.

1 April 2016
Verified
Book Chapter
Closed access
PDF file
NDNian Dong
Nian Dong
LSLin Shi
Lin Shi
CCChengshui Chen
Chengshui Chen
WMWenhuan Ma
Wenhuan Ma
XWXiangdong Wang
Xiangdong Wang

30 October 2026 in Cell Biology and Toxicology
Verified
Journal Article
Open access
PDF file
YXYiding Xu
Yiding Xu
MWMinghui Wang
Minghui Wang
YZYichun Zhu
Yichun Zhu
XZXiaodan Zhu
Xiaodan Zhu
JLJie Liu
Jie Liu
LSLin Shi
Lin Shi
Triazole antifungal drugs (TADs) are widely used for pulmonary mycosis but carry hepatotoxicity risks with incompletely understood mechanisms. This study aimed to characterize TADs-associated liver injury through integrated clinical and comprehensive bioinformatics analysis. A retrospective cohort of 199 pulmonary mycosis patients receiving TAD monotherapy was analyzed. Liver injury was defined by CIOMS/DILIN/ DEWG criteria; adverse events by Common Terminology Criteria for Adverse Events (CTCAE) v6.0. Independent risk factors were identified using Kaplan–Meier curves and multivariable Cox regression, and prediction models were developed and internally validated. Concurrently, TADs targets were predicted from multiple databases and intersected with hepatotoxicity genes. Transcriptomic validation was performed using bulk and single-cell RNA-seq data from cholestatic liver injury patients. Molecular docking, cell–communication analysis, and virtual knockout experiments were conducted to elucidate underlying mechanisms. Incidences of liver adverse events and injury were 31.7% and 11.6%, respectively; voriconazole showed the highest rates. Cholestatic injury predominated. High baseline ALT, AST, GGT, ALP, and immunocompromised status were independent risk factors. The prediction model achieved an optimism-corrected C-index of 0.73. Integrative transcriptomic and computational analysis identified KDR as the only shared target with strong binding to all three TADs. KDR was upregulated in cholestatic liver injury, with enhanced VEGFA–KDR signaling between Kupffer cells and endothelial cells. Virtual knockout implicated apoptosis, hypoxia, inflammation, and VEGF pathways. This study provides a comprehensive characterization of TADs-associated liver injury, identifying key risk factors and KDR as a candidate shared hepatotoxicity target, offering insights for risk stratification and potential therapeutic intervention.